Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Blocking Interfering Microbes: Irinotecan is a widely used anticancer pro-drug that is converted in the liver into the active form, but when it gets into the gut, the normally benign microbial flora can convert it into the toxic form, which kills the rapidly multiplying gut epithelium as it would kill rapidly dividing tumor cells, and thus causes diarrhea. Wallace et al. (p. 831 ; see the Perspective by Patel and Kaufmann ) used high-throughput screening to identify inhibitors that target the offending bacterial enzyme, β-glucuronidase, without killing the bacteria or affecting orthologous mammalian enzymes. Crystal structures revealed the molecular basis of selectivity, and in vivo studies showed that an inhibitor protected mice from irinotecan-induced toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Taken together, this functional metabolic repertoire includes the capacity for clinically relevant activation (e.g., sulfasalazine) (Peppercorn and Goldman, 1972b), reactivation (e.g., irinotecan/SN-38) (Wallace et al., 2010), and detoxification (e.g., digoxin) (Haiser et al., 2013) of xenobiotics with broad implications for drug action and toxicity (see Table 1).”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
The cited source says what the claim attributes to it.
In the citing paper
“Toxic or adverse consequences can also ensue, as is the case for irinotecan (Wallace et al., 2010)”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Wallace et al., 2010
In the citing paper
“Notably, β-glucuronidase inhibitors are capable of rescuing mice from drug toxicity.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“This specificity towards the bacterial enzymes was revealed with the assistance of crystallography and bioinformatics, which demonstrated that these inhibitors interacted with a “bacterial loop” that is highly conserved and well distributed across the gut bacteria enzymes, but is absent from the mammalian enzyme146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
In the citing paper
“The answer appears to be yes for the bacterial β-glucuronidases, for which multiple inhibitors now exist that have minimal impact on the mammalian homolog143–146.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [146]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
Gut flora in health and disease
Guarner, F., & Malagelada, J.-R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,365
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
CDD: specific functional annotation with the Conserved Domain Database
Marchler-Bauer, A., Anderson, J. B., Chitsaz, F., Derbyshire, M. K., DeWeese-Scott, C., Fong, J. H., Geer, L. Y., Geer, R. C., Gonzales, N. R., Gwadz, M., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn845 · Cited by 1,071
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen, R. H. J., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · PubMed · Cited by 740
Three-dimensional structure of β-galactosidase from E. coli.
Jacobson, R. H., Zhang, X.-J., DuBose, R. F., & Matthews, B. W. (1994) · Nature · doi:10.1038/369761a0 · Cited by 600
Research works printed but not linked: 4
- Mathijssen RHJ Clin Cancer Res 7 2182 2001 11489791
- Basińska A Floriańczyk B Ann Univ Mariae Curie Sklodowska Med 58 386 2003 15323223
- Jain S Nat Struct Mol Biol 3 375 1996 · DOI · Paper page
- Brattain MG Fine WD Khaled FM Thompson J Brattain DE Cancer Res 41 1751 1981 7214343
Cited by
Items 501–600 of 1,001
Zhao, W., Bai, J.-K., Li, H., Chen, T., & Ya-jie Tang, A. (2015) · Scientific Reports · doi:10.1038/srep10172 · Cited by 26
Feng, X., Tang, H. L., Han, B., Lv, B., & Li, C. (2016) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.6b00535 · Cited by 26
Maurice, C. F., & Turnbaugh, P. J. (2013) · FEMS Microbiology Reviews · doi:10.1111/1574-6976.12022 · Cited by 32
Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment
Sadeghloo, Z., & Sadeghi, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-03574-0 · Cited by 24
Deciphering the universal role of gut microbiota in pollutant transformation
Hou, R., Jin, X., Feng, J., Xue, J., Chen, C., Zou, Y., Xu, X., Yu, K., Qian, P., Zhang, W., et al. (2025) · The ISME Journal · doi:10.1093/ismejo/wraf215 · Cited by 25
Little, M. S., Ervin, S. M., Walton, W. G., Tripathy, A., Xu, Y., Liu, J., & Redinbo, M. R. (2018) · Protein Science · doi:10.1002/pro.3507 · Cited by 25
Self-citationGong, X., Liu, Y., Liu, X., Li, A. Q., Guo, K., Zhou, D., & Hong, Z. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105340 · Cited by 25
Muccee, F., Ghazanfar, S., Ajmal, W., & Al-Zahrani, M. (2022) · Genes · doi:10.3390/genes13091545 · Cited by 28
Wei, B., Wang, P., Yan, Z., & Yan, R. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9285-x · Cited by 25
HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases
Herrera, S., Martínez‐Sanz, J., & Villar, S. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01466 · Cited by 29
Yang, F., Zhu, W., Sun, S., Ai, Q., Edirisuriya, P., & Zhou, K. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b00279 · Cited by 25
Novel Forms of Immunomodulation for Cancer Therapy
del Valle, A. S., Naval, J., Anel, A., & Marzo, I. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.015 · Cited by 26
Chemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron
Keller, L. J., Nguyen, T. H., Liu, L. J., Hurysz, B. M., Lakemeyer, M., Guerra, M., Gelsinger, D. J., Chanin, R., Ngo, N., Lum, K. M., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01357-8 · Cited by 24
Drevland, O. M., de Muinck, E. J., Trosvik, P., Hammerstad, M., Kvitne, K. E., Midtvedt, K., Åsberg, A., & Robertsen, I. (2025) · Microbiome · doi:10.1186/s40168-025-02142-6 · Cited by 24
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 35
The Emerging Role of Microbiota and Microbiome in Pancreatic Ductal Adenocarcinoma
Čierniková, S., Novisedláková, M., Cholujová, D., Števurková, V., & Mego, M. (2020) · Biomedicines · doi:10.3390/biomedicines8120565 · Cited by 24
Microenvironmental Factors that Shape Bacterial Metabolites in Inflammatory Bowel Disease
Lopez, L. R., Ahn, J.-H., Alves, T., & Arthur, J. C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934619 · Cited by 25
Braccia, D. J., Ndjite, G. M., Weiss, A., Levy, S., Abeysinghe, S., Jiang, X., Pop, M., & Hall, B. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000898 · Cited by 24
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
Microbiota-gut-brain axis and ketogenic diet: how close are we to tackling epilepsy?
Mengoli, M., Conti, G., Fabbrini, M., Candela, M., Brigidi, P., Turroni, S., & Barone, M. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.24 · Cited by 25
Liu, W. L., Pi, Z., Wang, X., Shang, C., Song, C., Wang, R., He, Z., Zhang, X., Wan, Y., & Mao, W. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104322 · Cited by 25
Gut microbiota and immunosenescence in cancer
Xu, Y., He, C., Xi, Y., Zhang, Y., & Bai, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.004 · Cited by 24
Park, R., Umar, S., & Kasi, A. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00456-1 · Cited by 28
Spot-light on microbiota in obesity and cancer
Marzullo, P., Bettini, S., Menafra, D., Aprano, S., Muscogiuri, G., Barrea, L., Savastano, S., Colao, A., Colao, A., Savastano, S., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00866-7 · Cited by 25
Pensec, C., Gillaizeau, F., Guénot, D., Bessard, A., Carton, T., Leuillet, S., Campone, M., Neunlist, M., Blottière, H. M., & Vacon, F. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-65792-6 · Cited by 24
Gutsy science: In vitro systems of the human intestine to model oral drug disposition
Arian, C. M., Imaoka, T., Yang, J., Kelly, E. J., & Thummel, K. E. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107962 · Cited by 23
Wu, M., Wu, Z., Zou, Q., Wang, J., Kam, C., Chen, S., & Feng, S. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140189 · Cited by 23
Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory
Artusa, V., Calabrone, L., Mortara, L., Peri, F., & Bruno, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054997 · Cited by 24
Zhang, H., Jin, K., Xiong, K., Jing, W., Pang, Z., Feng, M., & Cheng, X. (2023) · Cancer Medicine · doi:10.1002/cam4.6194 · Cited by 23
Karan, S., Cho, M. Y., Lee, H.-S., Kim, H. M., Park, H. S., Han, E. H., Sessler, J. L., & Hong, K. S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01274 · Cited by 23
The impact of the human gut microbiome on the treatment of autoimmune disease
Nayak, R. R., & Orellana, D. A. (2024) · Immunological Reviews · doi:10.1111/imr.13358 · Cited by 24
Bell, J. A., Ho, K. L., & Farid, R. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912017453 · Cited by 23
Feng, X., Tang, H. L., Han, B., Zhang, L., Lv, B., & Li, C. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7630-5 · Cited by 23
Wilmes, P., Calatayud, M., & Tom, V. D. W. (2018) · Current Opinion in Microbiology · doi:10.1016/j.mib.2018.07.001 · Cited by 26
The rise and evolving role of Fusobacterium nucleatum subspecies
Wolf, M., Steinberg, T., Scholz, K. J., Kruse, A., Rezasoltani, S., Conrads, G., Al‐Ahmad, A., & Cieplik, F. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100414 · Cited by 24
Liu, L., Liang, L., Liang, H., Wang, M., Zhou, W., Mai, G., Yang, C., & Chen, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.017 · Cited by 22
Garg, S., Sharma, N., Bharmjeet, & Das, A. (2023) · Cancer Reports · doi:10.1002/cnr2.1892 · Cited by 27
The Impact of Microbiota–Immunity–Hormone Interactions on Autoimmune Diseases and Infection
Martinelli, S., Nannini, G., Cianchi, F., Coratti, F., & Amedei, A. (2024) · Biomedicines · doi:10.3390/biomedicines12030616 · Cited by 25
The role of gut microbial β-glucuronidases in carcinogenesis and cancer treatment: a scoping review
Hillege, L. E., Stevens, M. A. M., Kristen, P. A. J., de Vos‐Geelen, J., Penders, J., Redinbo, M. R., & Smidt, M. L. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06028-2 · Cited by 23
Self-citationWu, B. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22827 · Cited by 22
Plotnikoff, G. A. (2014) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.021 · Cited by 23
Han, B., Hou, Y., Jiang, T., Lv, B., Zhao, L., Feng, X., & Li, C. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b03449 · Cited by 22
Hazen, S. L., & Smith, J. D. (2012) · Circulation Research · doi:10.1161/circresaha.112.277277 · Cited by 23
Woloszynek, S., Pastor, S. J., Mell, J. C., Nandi, N., Sokhansanj, B. A., & ROSEN, G. L. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.01.003 · Cited by 26
Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases
Mohandas, S., & Vairappan, B. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i32.1210 · Cited by 21
Sun, R., Basu, S., Zeng, M., Sunsong, R., Li, L., Ghose, R., Wang, W. J., Liu, Z., Hu, M., & Gao, S. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666181029153255 · Cited by 21
Li, X., Hua, L., Zhou, T., Wang, K.-B., Wu, Y., Emam, M., Bao, X., Chen, J., & Wei, B. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1780225 · Cited by 21
The Implication of Gastric Microbiome in the Treatment of Gastric Cancer
Pappas‐Gogos, G., Tepelenis, K., Fousekis, F., Katsanos, K. H., Pitiakoudis, M. S., & Vlachos, K. (2022) · Cancers · doi:10.3390/cancers14082039 · Cited by 23
The intestinal microbiota in colorectal cancer metastasis – Passive observer or key player?
Patel, M., McAllister, M. J., Nagaraju, R. T., Al-Badran, S. S. F., Edwards, J., McBain, A. J., Barriuso, J., & Aziz, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103856 · Cited by 21
Loganathan, T., & Doss, C. G. P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121118 · Cited by 22
Li, P., Zhang, R., Zhou, J., Guo, P., Liu, Y., & Shi, S. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2310277 · Cited by 22
Khorashadizadeh, S., Abbasifar, S., Yousefi, M., Fayedeh, F., & Ghalibaf, A. M. (2024) · Cancer Reports · doi:10.1002/cnr2.70029 · Cited by 23
The human microbiome: redefining cancer pathogenesis and therapy
Adlakha, Y. K., & Chhabra, R. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03787-x · Cited by 25
Lucafò, M., Franzin, M., Lagatolla, C., Franca, R., Bramuzzo, M., Stocco, G., & Decorti, G. (2019) · Clinical and Translational Science · doi:10.1111/cts.12722 · Cited by 22
Lai, Y., Dhingra, R., Zhang, Z., Ball, L. M., Zylka, M. J., & Lü, K. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00656 · Cited by 23
Properties and structures of β-glucuronidases with different transformation types of glycyrrhizin
Wang, X., Liu, Y., Wang, C., Feng, X., & Li, C. (2015) · RSC Advances · doi:10.1039/c5ra11484e · Cited by 21
Adsorption ofβ-glucuronidase and estrogens on pectin/lignin hydrogel particles
Borisenkov, M. F., Карманов, А. П., Kocheva, L. S., Александрович, М. П., Istomina, E. I., Bakutova, L. A., Геннадьевич, Л. С., Александровна, М. Е., Durnev, E. A., Vityazev, F. V., et al. (2015) · International Journal of Polymeric Materials · doi:10.1080/00914037.2015.1129955 · Cited by 21
The Microbiome and Its Potential for Pharmacology
Chavira, A., Belda‐Ferre, P., Kościółek, T., Ali, F., Dorrestein, P. C., & Knight, R. D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_317 · Cited by 22
Shankaran, H., Cronin, A., Barnes, J., Sharma, P., Tolsma, J., Jasper, P., & Mettetal, J. T. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12255 · Cited by 20
Bai, X., Deng, J., Duan, Z., Fu, R., Zhu, C., & Fan, D. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155577 · Cited by 20
Kenneth, M. J., Wu, C.-C., Fang, C., Hsu, T.-K., Lin, I., Huang, S.-W., Chiu, Y., & Hsu, B. (2025) · Antibiotics · doi:10.3390/antibiotics14030264 · Cited by 21
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies
du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 22
Connecting the dots: Targeting the microbiome in drug toxicity
Luo, Y., & Zhou, T. (2021) · Medicinal Research Reviews · doi:10.1002/med.21805 · Cited by 21
Microbial metabolites as modulators of host physiology
Joyce, S. A., & Clarke, D. J. (2024) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2023.12.001 · Cited by 23
The Microbiome Modulates the Immune System to Influence Cancer Therapy
Roy, R., & Singh, S. K. (2024) · Cancers · doi:10.3390/cancers16040779 · Cited by 20
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 21
Rooks, M. G., & Garrett, W. S. (2011) · F1000 Biology Reports · doi:10.3410/b3-12 · Cited by 25
Lu, L., Zhuang, T., Shao, E., Liu, Y., He, H., Shu, Z., Huang, Y., Yao, Y., Lin, S., Lin, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221964 · Cited by 20
Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer
Paulík, A., Grim, J., & Filip, S. (2012) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2015.39 · Cited by 22
Structural studies of a cold-adapted dimeric β- D -galactosidase fromParacoccussp. 32d
Rutkiewicz, M., Pietrzyk‐Brzezinska, A. J., Sekula, B., Cieśliński, H., Wierzbicka-Woś, A., Kur, J., & Bujacz, A. (2016) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798316012535 · Cited by 20
Yu, Y., Kong, R., Cao, H., Yin, Z., Liu, J., Xiang, N., Phan, A. T., Ding, T., Zhao, H., & Wong, S. T. C. (2018) · Oncotarget · doi:10.18632/oncotarget.24563 · Cited by 20
Getting Lost in the Cell–Lysosomal Entrapment of Chemotherapeutics
Zhai, X., & Hiani, Y. E. (2020) · Cancers · doi:10.3390/cancers12123669 · Cited by 21
Bacterial infections in cancer: A bilateral relationship
Basu, A., Singh, R., & Gupta, S. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1771 · Cited by 21
A new evaluation system for drug–microbiota interactions
Liu, T., Zhang, C., Zhang, H., Jin, J., Li, X., Liang, S., Xue, Y., Yuan, F., Zhou, Y., Bian, X., et al. (2024) · iMeta · doi:10.1002/imt2.199 · Cited by 19
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
Review of nutritional status, body composition, and effects of antineoplastic drug disposition
Wiernikowski, J. T., & Bernhardt, M. B. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28207 · Cited by 20
Lipopeptide(s) associated with human microbiome as potent cancer drug
Chauhan, V., & Kanwar, S. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.012 · Cited by 19
Wu, M., Liu, L., Zou, Q., Leung, J., Wang, J., Chou, T. Y., & Feng, S. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01669a · Cited by 19
Leigh, S., Lynch, C. M. K., Bird, B., Griffin, B. T., Cryan, J. F., & Clarke, G. A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2043849 · Cited by 19
Liu, Y., Huangfu, J., Qi, F., Kaleem, I., Wenwen, E., & Li, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030998 · Cited by 19
The microbiota in breast cancer: dysbiosis, microbial metabolites, and therapeutic implications
Liu, Y. (2025) · American Journal of Cancer Research · doi:10.62347/zjcf2843 · Cited by 19
The mechanisms and therapeutic potential of the microbiome-immune interface in cancer
Christina, B., Poongkuzhali, S., Muninathan, N., Bhaskaran, K., & Suresh, A. (2025) · Discover Biotechnology · doi:10.1007/s44340-025-00031-0 · Cited by 18
Yu, H., Cheng, Y., Wu, C.-M., Ran, K., Wei, B., Xu, Y., Shan, W., Ying, Y., & Zhan, Z. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113106 · Cited by 18
Kim, A. J., Hong, D. S., & George, G. C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102408 · Cited by 21
DNA Damage and the Gut Microbiome: From Mechanisms to Disease Outcomes
Hsiao, Y.-C., Liu, C., Yang, Y., Feng, J., Zhao, H., & Lü, K. (2023) · DNA · doi:10.3390/dna3010002 · Cited by 22
Cheng, T.-C., Chuang, K.-H., Roffler, S. R., Cheng, K.-W., Leu, Y.-L., Chuang, C., Huang, C.-C., Kao, C.-H., Hsieh, Y.-C., Chang, L., et al. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/740815 · Cited by 19
Host–microbe interactions and spatial variation of cancer in the gut
Shanahan, F., & O’Toole, P. W. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3765 · Cited by 18
Modulating the Human Gut Microbiome as an Emerging Therapeutic Paradigm
Rajpal, D. K., & Brown, J. R. (2013) · Science Progress · doi:10.3184/003685013x13691404141587 · Cited by 19
Joukar, F., Mavaddati, S., Mansour‐Ghanaei, F., & Samadani, A. A. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00237-6 · Cited by 19
Drugging the gut microbiota: toward rational modulation of bacterial composition in the gut
Altamura, F., Maurice, C. F., & Castagner, B. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.09.005 · Cited by 18
Zhou, T., Wei, B., He, M., Li, Y., Wang, Y., Wang, S., Chen, J., Zhang, H., Cui, Z., & Wang, H. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1816998 · Cited by 18
Self-citationLi, F., Yan, S., Huang, Z., Gao, W., Zhang, S., Mo, S., Lin, S. J., Wang, J., Hu, Z., & Zhang, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104826 · Cited by 18
Pancreatic Cancer Resistance to Treatment: The Role of Microbiota
Nista, E. C., GAUDIO, A. D., Vecchio, L. E. D., Mezza, T., Pignataro, G., Piccioni, A., Gasbarrini, A., Franceschi, F., & Candelli, M. (2023) · Biomedicines · doi:10.3390/biomedicines11010157 · Cited by 18
Self-immolative trigger-initiated polydiacetylene probe for β-glucuronidase activity
Wang, D., Zhang, Y., Li, T., Tu, Q., & Wang, J. (2014) · RSC Advances · doi:10.1039/c4ra01816h · Cited by 18
The implementation of omics technologies in cancer microbiome research
Mullish, B. H., Osborne, L. S., Marchesi, J. R., & McDonald, J. A. K. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.864 · Cited by 19
Systematic mapping of drug metabolism by the human gut microbiomePreprint
Chankhamjon, P., Javdan, B., Lopez, J. G., Hull, R., Chatterjee, S., & Donia, M. S. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/538215 · Cited by 19
Ecological management of the microbiota in patients with cancer
Xavier, J. B. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01049-3 · Cited by 18
Impact of Gut Microbiota on Drug Metabolism and Absorption
Burke, K., & Li, Y. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00429-8 · Cited by 17
Tutorial: Microbiome studies in drug metabolism
Dodd, D., & Cann, I. (2022) · Clinical and Translational Science · doi:10.1111/cts.13416 · Cited by 17
Kyaw, T. S., Upadhyay, V., Tolstykh, I. V., Loon, K. V., Laffan, A., Stanfield, D., Gempis, D., Kenfield, S. A., Chan, J. M., Piawah, S., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.07.011 · Cited by 18
Metadata
- Authors
- Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., & Redinbo, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Albert Einstein College of Medicine (US)
- North Carolina Central University (US)
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 831-835
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3110694
- OpenAlex
- W2140145798
- Cited by
- 1,080
- References
- 39
- Citations by year
- 2026: 97 · 2025: 80 · 2024: 103 · 2023: 101 · 2022: 92 · 2021: 92 · 2020: 100 · 2019: 82 · 2018: 70 · 2017: 67 · 2016: 47 · 2015: 33 · 2014: 34 · 2013: 28 · 2012: 29
- FWCI
- 25.42
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Damon Runyon Cancer Research Foundation
- Golden LEAF Foundation
- National Institutes of Health
- National Cancer Institute (CA 127231, R01CA161879, R01CA127231, CA98468, R01CA098468)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073338)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, chemotherapy-induced diarrhea, enzyme inhibitors, gut microbiota, commensal bacteria, substrate specificity, crystal structure, high-throughput screening, oral administration, colon cancer, drug toxicity
- MeSH terms
- Irinotecan, Animals, Antineoplastic Agents, Phytogenic, Bacteria, Anaerobic, Camptothecin, Colon, Diarrhea, Drug Evaluation, Preclinical, Enzyme Inhibitors, Escherichia coli, Female, Glucuronidase, Humans, Intestinal Mucosa, Mice, Inbred BALB C, Models, Molecular, Prodrugs, Protein Conformation, Crystallography, X-Ray, Escherichia coli Proteins, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.